Sökning: WFRF:(Maria Langkilde Anna) >
Glucagon Levels Dur...
Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes.
-
- Lundkvist, Per (författare)
- Uppsala universitet,Klinisk diabetologi och metabolism
-
- Pereira, Maria J., 1981- (författare)
- Uppsala universitet,Klinisk diabetologi och metabolism
-
- Kamble, Prasad G. (författare)
- Uppsala universitet,Klinisk diabetologi och metabolism
-
visa fler...
-
- Katsogiannos, Petros (författare)
- Uppsala universitet,Klinisk diabetologi och metabolism
-
- Langkilde, Anna Maria (författare)
- AstraZeneca Res & Dev, S-43150 Molndal, Sweden
-
- Esterline, Russell (författare)
- AstraZeneca Res & Dev, S-43150 Molndal, Sweden
-
- Johnsson, Eva (författare)
- AstraZeneca Res & Dev, S-43150 Molndal, Sweden
-
- Eriksson, Jan W. (författare)
- Uppsala universitet,Klinisk diabetologi och metabolism
-
visa färre...
-
(creator_code:org_t)
- 2018-08-17
- 2019
- Engelska.
-
Ingår i: Journal of Clinical Endocrinology and Metabolism. - : The Endocrine Society. - 0021-972X .- 1945-7197. ; 104:1, s. 193-201
- Relaterad länk:
-
https://academic.oup...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Context: The mechanism mediating sodium glucose cotransporter-2 (SGLT2) inhibitor-associated increase in glucagon levels is unknown.Objective: To assess short-term effects on glucagon, other hormones, and energy substrates after SGLT2 inhibition and whether such effects are secondary to glucose lowering. The impact of adding a dipeptidyl peptidase-4 inhibitor was addressed.Design, Setting, and Patients: A phase 4, single-center, randomized, three-treatment crossover, open-label study including 15 patients with type 2 diabetes treated with metformin.Interventions: Patients received a single-dose of dapagliflozin 10 mg accompanied by the following in randomized order: isoglycemic clamp (experiment DG); saline infusion (experiment D); or saxagliptin 5 mg plus saline infusion (experiment DS). Directly after 5-hour infusions, a 2-hour oral glucose tolerance test (OGTT) was performed.Results: Glucose and insulin levels were stable in experiment DG and decreased in experiment D [P for difference (Pdiff) < 0.001]. Glucagon-to-insulin ratio (Pdiff < 0.001), and levels of glucagon (Pdiff < 0.01), nonesterified fatty acids (Pdiff < 0.01), glycerol (Pdiff < 0.01), and β-OH-butyrate (Pdiff < 0.05) were lower in DG vs D. In multivariate analysis, change in glucose level was the main predictor of change in glucagon level. In DS, glucagon and active GLP-1 levels were higher than in D, but glucose and insulin levels did not differ. During OGTT, glucose levels rose less and glucagon levels fell more in DS vs D.Conclusion: The degree of glucose lowering markedly contributed to regulation of glucagon and insulin secretion and to lipid mobilization during short-term SGLT2 inhibition.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas